Stem reported record Q4 2022 revenue of $156 million, a 194% increase year-over-year. The company also reported record bookings of $458 million and a contracted backlog of $969 million. They are introducing full-year 2023 guidance and reaffirm plan to achieve positive adjusted EBITDA in 2H’2023.
Record revenue of $156 million, up 194% from Q4 2021.
GAAP gross margin increased to 8% from (3)% in Q4 2021.
Record bookings of $458 million, up 111% year-over-year.
Contracted backlog of $969 million, up from $817 million in Q3 2022.
The Company’s full-year 2023 guidance ranges are as follows: Revenue $550 - $650 million, Non-GAAP Gross Margin (%) 15% - 20%, Adjusted EBITDA $(35) - $(5) million, Bookings $1,400 - $1,600 million, CARR (year-end) $80 - $90 million